Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study is an observational registry that gathers existing medical records of adults diagnosed with HCC from multiple sites. It includes patients diagnosed between 2015 and 2023 and follows them for at least six months after diagnosis to capture treatment and outcomes data. The aim is to describe disease characteristics, causes, and survival patterns in diverse populations, with a focus on regional differences in risk factors like HBV, HCV, cirrhosis, and steatotic liver disease. Interventions are not part of the study; data come from routine clinical care and record review. Participation is limited to sites in Egypt (Al Mansurah, Dakahlia, Damietta) under a sponsor-led observational framework.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a radiological or histopathological confirmed diagnosis with HCC in any stage of the tumor between 1st January 2015 and 31st December 2023 (defined as index date).
* Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written informed consent according to the local regulations
* Age 18 years or older, and a lawful adult in the country at the index date
* Patients with medical records, including etiology, laboratories, radiological, and treatment details will be collected from the participating sites.
* Patients with medical records covering at least a 6-month follow-up period, defined as the time from the index date (the date of the first diagnosis) to the earliest of the following: the patient's death, the last medical record entry, or the data extraction date. Additionally, patients who died within this 6-month period will also be included.

Exclusion Criteria:

* Patients with other cancer diagnosis on or before index date.
* Patients with records missing information on etiology, laboratory results, radiological findings, or treatment details (≥30% of key variables).
* Previously opted out of sharing medical records
* Patients participating in clinical trials
* Pregnant patient

Where it's running

• Research Site
  Al Ain City, United Arab Emirates Recruiting
• Research Site
  Al Mansurah, Egypt Not yet recruiting
• Research Site
  Dakahlia, Egypt Not yet recruiting
• Research Site
  Damietta, Egypt Not yet recruiting
• Research Site
  Menouf, Egypt Not yet recruiting
• Research Site
  Kuwait City, Kuwait Not yet recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• GLP-1 RA plus standard treatment in first-line metastatic GI cancers

  This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.

  Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT07627191

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.